Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SC 13G/A ProQR Therapeutics N.V. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A AERIE PHARMACEUTICALS Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A ORBCOMM Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A OLIN CORP Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A Advaxis, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A Intec Pharma Ltd. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A Adverum Biotechnologies, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A MOSAIC CO Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form D/A Adage Capital Partners,
-
Form SC 13G EAGLE MATERIALS INC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G ROCKET PHARMACEUTICALS, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cel
-
Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cel
-
Form SC 13G Under Armour, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G GMS Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Annexon Biosciences Closes $75 Million Financing
-
Form SC 13G AMCI Acquisition Corp. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G VAPOTHERM INC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A InflaRx N.V. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Sep 30
-
Cabaletta Bio Emerges Out of University of Pennsylvania to Develop CAAR T Cell Technology to Treat B Cell-mediated Autoimmune Diseases
-
Cabaletta Bio Emerges Out of University of Pennsylvania to Develop CAAR T Cell Technology to Treat B Cell-mediated Autoimmune Diseases
-
Form SC 13G Summit Materials, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G Eiger BioPharmaceuticals Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G Spring Bank Pharmaceutic Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G ARYA SCIENCES ACQUISITIO Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G Aeglea BioTherapeutics, Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Girls Who Invest Celebrates International Day of the Girl
-
Form SC 13G National Vision Holdings Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Tanium Accelerates Momentum: Secures $200 Million in Latest Funding Round Bringing Company Valuation to $6.5 Billion
-
Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
-
Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
-
Form SC 13G Spartan Energy Acquisiti Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Soros Fund Management adds popular tech names, BlackRock in second quarter
-
U.S. hedge funds bet on retail, tech in second-quarter as economy sizzled
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Jun 30
-
MedAvail Completes Financing Round, Adds Express Scripts as New Investor
-
Form SC 13G ARDELYX, INC. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G Xenon Pharmaceuticals Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs
-
Form SC 13G ProQR Therapeutics N.V. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13D/A AveXis, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Gene Therapy Market, 2030
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Mar 31
-
Form SC 13G Ferroglobe PLC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13D AveXis, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G Zosano Pharma Corp Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson’s and Other Neurodegenerative Diseases

